RheumaFinder is a medical imaging AI startup specializing in rheumatology and rheumatological radiology. Using advanced AI technology, RheumaFinder analyzes standard medical images to detect early signs of joint damage, addressing diagnostic delays and underdiagnosis in rheumatic diseases. Their mission is to ensure timely interventions for patients, preserving health and improving quality of life.

More on www.rheumafinder.ai



Altvao is medical device company based in Dresden, Germany. The ambition is harnessing the power of machine learning and state-of-the-art sensor technology to improve the lives of people who have lost their voice.

The first group to benefit are patients who have lost their voice box because of tumor surgery, a procedure known as laryngectomy. But there are many more potential applications of our technology, both in speech rehabilitation and in non-medical fields.

For info on https://www.altavo.eu/

Rarity Bioscience

Rarity superRCA is an ultrasensitive multiplex assay for detecting rare nucleic acid sequences in biological samples like liquid biopsies. The format and flexibility of the technology platform – and read-out based on flow cytometry – makes it suitable for research as well as clinical application.

See more https://raritybioscience.com/

C-mo Medical Solutions

C-mo Medical Solutions is an award-winning digital health company with an innovative solution for the diagnosis and management of cough-incident medical conditions. The company’s mission is to unravel the clinical potential of cough assessment and solve the major unmet medical needs associated with the management of chronic cough.

Find out more at www.c-mo.solutions.


Carroucell is disrupting the biomanufacturing sector with its patented, innovative microcarrier and flexible process solution for customers. The microcarriers are based on a major innovation in the field of sol-gel process, which allows the production of bioactive microstructures not achievable by existing technologies.

In the bioreactor, cells can cling and multiply in “3D” which allows cultivation of a large quantity of cells in a restricted volume. Carroucell has a partnership with Etablissement Français du Sang (EFS), which enabled the validation of its microcarriers and facilitated first commercial orders. Carroucell was founded in 2016 by Tarek Fathallah.

For more information, visit www.carroucell.com.

Alithea Genomics

Alithea Genomics has developed a proprietary technology called Bulk RNA Barcoding and sequencing (BRB-seq), which enables the preparation of hundreds of RNA samples for sequencing in a single tube. By drastically decreasing the cost and time associated with library preparation for RNA sequencing, the BRB-seq technology enables for the first time the application of high-content and unbiased gene expression analysis to very large-scale projects, such as biobank functionalization and high-throughput drug screening.

Alithea Genomics was founded in May 2020 at the EPFL in Lausanne, Switzerland. More information can be found at www.alitheagenomics.com.


Trince is dedicated to advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells, both in vitro and ex vivo. The company’s LumiPore transfection platform, which is covered by a portfolio of pending patents, is used to deliver a wide variety of effector molecules (e.g. nucleic acids or proteins) into virtually any cell type, including hard-to-transfect cells such as immune cells for cell therapies. The technology ensures that this is done in a gentle manner, maximizing the therapeutic quality of the final cell product. www.trincebio.com


Modality.AI, Inc. (“Modality”) has developed the first multimodal assessment platform to track the progression of neurological and psychiatric diseases through the analysis of facial musculature and phonetic enunciation, using a virtual agent to guide participants through standardized protocols. Modality’s rich, objective, and accurate audiovisual biomarkers expedite the development of therapies for diseases such as Parkinson’s, schizophrenia, depression, and autism, as well as the diagnosis and tracking of treatment efficacy at scale, as used by some of the leading clinical institutions in the world, including UCSF, MGH, NYU, Purdue, and the Charité.

Modality was founded by world-class AI experts with over 200 publications and issued patents and several successful exits. Modality is venture backed and based in San Francisco, CA.


RheaVita has developed a continuous, controlled freeze-drying technology that integrates all the traditional freeze-drying process steps into one continuous production line.

By spinning the glass vials during the freezing process, a thin layer of product coats the inner lining of the vial. Following drying, the final solid freeze-dried product is obtained. Compared to the traditional freeze-drying process, RheaVita’s approach has several advantages, including very fast product and process development with limited experimental efforts, avoiding scale-up issues, reducing cycle times, lower production costs, less clean room space requirements, improving quality assurance and improved and uniform product quality and process uniformity.


Grapheal develops wearable and disposable biosensors enabling continuous monitoring and in-field diagnosis. It empowers caregivers with an improved and individualized assessment tool for precision medicine. See more on www.grapheal.com


Enzyre, based in Nijmegen, The Netherlands, is a spin-out from Radboud University Medical Center, developing Enzypad, a near patient diagnostic and monitoring device initially focused on blood coagulation. Enzyre’s platform technology is unique as it requires just a small volume of blood and is able to measure up to twelve (12) biomarkers simultaneously without any laboratory infrastructure; at home, on the road or in a critical care setting. Enzyre’s proprietary technology is a small hand-held diagnostic tool using disease specific single use microfluidic cartridges with high sensitivity and specificity. It has broad applicability in several disease areas.


EXITED – Cergentis was acquired by Solvias

Cergentis is an innovative leader in genomics, provides kits and services based on its proprietary Targeted Locus Amplification (TLA) technology to leading diagnostic labs, research institutes and pharmaceutical companies worldwide.


Fertiga (fertiga.com) is a spin-off from Vrije Universiteit Brussel (VUB) on the basis of research carried out over the past 10 years within the VUB and University hospital of Brussels (UZ Brussels). Our objective is to become a major player in improving fertility treatment outcomes. We improve efficiency of IVF by analysis of gene expressions in cells surrounding the egg cell. Our goal is to reach ‘one child with one try’.



Epigenetic Biomarkers for Cancer Diagnosis and Personalized Treatment

Epify develops epigenetic biomarkers which control gene activity and are implicated in a wide range of cancers, driving and influencing the course of the disease. Using these biomarkers, Epify aims to drive earlier detection and more accurate diagnosis, facilitating personalized oncology and a better prognosis for cancer patients.



EXITED – Doc.ai was acquired by Sharecare

Doc.ai wants to break down data silos and transform healthcare with the power of artificial intelligence. End users can collect all their medical information in the doc.ai app.

myNEO Therapeutics

myNEO Therapeutics is a distinguished biopharmaceutical powerhouse, dedicated to pioneer breakthrough immunotherapies to fight cancer. myNEO Therapeutics is leveraging its ImmunoEngine discovery platform to tap into novel promising tumor targets found in the dark genome – named camyotopes™ – which have the potential to unlock immunotherapy for large patient populations who currently do not respond.


OhmX.bio is a spin-off initiative @ the Ghent University offering R&D through cutting-edge technologies to help our customers resolve their biological questions, providing a full trajectory from sample preparation to data analysis of the results. We offer next generation wet-lab solutions to our customers in the field of transcriptomics, translatomics, proteomics and epigenetics.


BioLizard (Lizard.Bio) is founded to provide bioinformatics solutions for customers in biotech, pharma and academia. As life science research is rapidly evolving into a more data-driven field, there is a niche and a high demand for this type of applications. Lizards adapt to their biological environment. Likewise, we strive towards offering state-of-the-art bioinformatics, statistics and machine learning solutions to help solve biological questions by adapting to the needs and data of our customers.